 | Steve R. Carchedi
DirectorSteve R. Carchedi
Director
Currently, Mr. Carchedi serves as the President, Commercial Operations for Mallinckrodt Specialty Pharmaceuticals, the Pharmaceuticals business of Covidien plc. Having held key positions at several leading multinational pharmaceutical companies, Mr. Carchedi brings more than 30 years of commercial industry experience focused in Oncology, Neurology, Urology, Endocrinology and Cardiology. In addition to his industry experience, Mr. Carchedi currently serves on the Board of Directors of BioNumerick... |
|
 |
| Matthew K. Fust
DirectorMatthew K. Fust
Director
Matthew Fust has served as a member of our board of directors since 2005. Mr. Fust is the Chief Financial Officer of Onyx Pharmaceuticals, Inc. From 2003 to 2008 he was Chief Financial Officer of Jazz Pharmaceuticals, Inc., and from May 2002 to May 2003 Mr. Fust was Chief Financial Officer at Perlegen Sciences, Inc., a biotechnology company. From June 1996 to January 2002, he was an executive with ALZA Corporation, first as Controller and then as Chief Financial Officer. Mr. Fust holds a B.A. in... |
|
|
| Ed Hurwitz
DirectorEd Hurwitz
Director
Ed Hurwitz has served as a member of our board of directors since April 2009. Mr. Hurwitz has served as a director of Alta Partners since June 2002. From June 1997 to October 2002, Mr. Hurwitz served as Senior Vice President and Chief Financial Officer of Affymetrix, Inc., a microarray technology company. From April 1994 to June 1997, Mr. Hurwitz was a biotechnology research analyst for Robertson Stephens & Company, and from April 1992 to April 1994, was a biotechnology research analyst for Smit... |
|
|
| Steven B. Ketchum, Ph.D.
DirectorSteven B. Ketchum, Ph.D.
Director
Dr. Ketchum was elected to the board of directors in February 2012 after serving as Senior Vice President, Research and Development for Sunesis since 2008. Dr. Ketchum currently is the President of Research and Development, Senior Vice President at Amarin Corporation where he is responsible for Amarin’s drug discovery, preclinical and clinical development program and regulatory and medical affairs activities. At Sunesis, prior to Amarin, Dr. Ketchum, as a member of the Executive Committee, prov... |
|
|
| Helen Kim
DirectorHelen Kim
Director
Ms. Kim is currently the Interim Chief Executive Officer of privately held Cyterix Pharmaceuticals, Inc. She also serves as a Director of ImmunoCellular Therapeutics, Forsight VISION 4, and as a Strategic Advisor to NGM Biopharmaceuticals, Inc., where she had served as Chief Business Officer. Previously, she served as a Director and Chief Executive Officer of privately held TRF Pharma, Inc. She was the Chief Executive Officer and President of Kosan Biosciences Incorporated where she restructur... |
|
|
| Dayton Misfeldt
DirectorDayton Misfeldt
Director
Dayton Misfeldt has served as a member of our board of directors since April 2009. Mr. Misfeldt is an Investment Partner at Bay City Capital LLC and focuses on biopharmaceutical investment opportunities. Prior to joining Bay City Capital in May 2000, Mr. Misfeldt was a Vice President at Roth Capital Partners where he worked as a sell-side analyst covering the biopharmaceutical industry. Mr. Misfeldt has also worked as a Project Manager at Life Science Economics. Mr. Misfeldt received a B.A. in E... |
|
|
| Homer L. Pearce, Ph.D.
DirectorHomer L. Pearce, Ph.D.
Director
Dr. Pearce has served as a member of our board of directors since June 2006. Dr. Pearce served in various capacities at Eli Lilly & Company since joining the company in 1979, including Vice President, Cancer Research and Clinical Investigation from 1994 to 2002 and Fellow, Cancer Research, Lilly Research Laboratories from 2002 to March 2006. Since August 2006, Dr. Pearce has served as a consultant to our company. He is a member of the American Association for Cancer Research, the American Chemic... |
|
|
| David C. Stump, M.D.
DirectorDavid C. Stump, M.D.
Director
Dr. Stump has served as a member of our board of directors since June 2006. He is Executive Vice President, Research and Development at Human Genome Sciences, Inc., and has served at the company since November 1999. Prior to joining Human Genome Sciences, Dr. Stump held roles of increasing responsibility at Genentech, Inc., from 1989 to 1999, most recently as Vice President, Clinical Research and Genentech Fellow. Prior to joining Genentech, Dr. Stump was an Associate Professor of Medicine and B... |
|
|
| Daniel N. Swisher, Jr.
Chief Executive Officer and PresidentDaniel N. Swisher, Jr.
Chief Executive Officer and President
Since December 2003, Daniel N. Swisher, Jr. has served as Chief Executive Officer and a member of the Sunesis Board of Directors, and as our President since August 2005. Mr. Swisher joined the company in 2001 and he served as Chief Business Officer and Chief Financial Officer until 2003. Prior to joining Sunesis, Mr. Swisher served in various management roles, including Senior Vice President of Sales and Marketing for ALZA Corporation from 1992 to 2001. Mr. Swisher joined the board of the Okizu ... |
|
|
| James W. Young, Ph.D.
ChairmanJames W. Young, Ph.D.
Chairman
Since April 2009, James W. Young, Ph.D. has been non-executive Chairman of our board of directors. From 2000 until April 2009 Dr Young served as Executive Chairman. Dr. Young was the Chief Executive Officer of Sunesis from May 2000 until November 2003. In April 2006, Dr. Young joined 5AM Ventures, a venture capital firm, as a venture partner. Prior to joining Sunesis, Dr. Young served as Vice President for Research; Senior Vice President, Research and Development; and Group Vice President at ALZ... |
|
|
